Previous 10 | Next 10 |
MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Susan M. Kanaya, the Company’s Executive Vice President and Chief Financial and Administrative Officer, to the ChemoCentryx Board of Directors effective Ma...
The following slide deck was published by ChemoCentryx, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: ChemoCentryx, Inc. 2020 Q4 - Results - Earnings Call Presentation
ChemoCentryx, Inc. (CCXI) Q4 2020 Earnings Conference Call March 01, 2021, 05:00 PM ET Company Participants Lee Roth - Investor Relations, Burns McClellan Thomas Schall - Chairman, President and Chief Executive Officer Susan Kanaya - Executive Vice President, Chief Financial and Administrativ...
Image source: The Motley Fool. ChemoCentryx Inc (NASDAQ: CCXI) Q4 2020 Earnings Call Mar 1, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: ChemoCentryx Inc (CCXI) Q4 2020 Earnings Call Transcript
ChemoCentryx (CCXI): Q4 GAAP EPS of -$0.43 misses by $0.10.Revenue of $4.36M (-56.6% Y/Y) misses by $3.63M.Press Release For further details see: ChemoCentryx EPS misses by $0.10, misses on revenue
-- The New England Journal of Medicine highlights results of ADVOCATE Phase III trial of avacopan in ANCA-associated vasculitis -- -- Applications for regulatory approval of avacopan in ANCA-associated vasculitis under review in the U.S. (PDUFA goal date of July 7, 2021), the E....
ChemoCentryx (CCXI) appointed 20-years industry veteran Tausif (Tosh) Butt as EVP & COO overseeing operational functions, and further strengthen the commercial infrastructure that ChemoCentryx has developed in anticipation of the launch of avacopan for the treatment of ANCA-associate...
-- Brings more than two decades of executive management experience from global pharmaceutical companies -- MOUNTAIN VIEW, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Tausif (‘Tosh’) Butt as Executive ...
MOUNTAIN VIEW, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2020 financial results will be released after market close on Monday, March 1, 2021. ChemoCentryx executive management will host a con...
ChemoCentryx (CCXI) has gained ~2.2% in the premarket after announcing that The New England Journal of Medicine has published the Phase 3 data from the ADVOCATE trial.The pivotal, randomized, double-blind, active-controlled, double-dummy study evaluated the orally-administ...
News, Short Squeeze, Breakout and More Instantly...
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...